Literature DB >> 20102304

Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid.

Ghulam Abbas1, Keith D Lindor.   

Abstract

IMPORTANCE OF THE FIELD: Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis. AREAS COVERED IN THIS REVIEW: The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 - 2009. WHAT WILL THE READER GAIN: The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not. TAKE-HOME MESSAGE: Ursodeoxycholic acid in a dose of 13 - 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102304     DOI: 10.1517/14656560903493460

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study.

Authors:  Enver Fekaj; Arben Gjata; Mehmet Maxhuni
Journal:  BMC Surg       Date:  2013-09-22       Impact factor: 2.102

2.  No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.

Authors:  Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2011-06-08       Impact factor: 2.953

Review 3.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08

4.  Changing Nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis".

Authors:  Atsushi Tanaka; Hajime Takikawa; Satoshi Mochida; Kazuhiko Koike; Hiroto Miwa; Toru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-26       Impact factor: 7.527

5.  Comparison of Cytotoxic Activity of Bile on HepG2 and CCRF-CEM Cell Lines: An in Vitro Study.

Authors:  Negar Azarpira; Fatemeh Rastegar; Maryam Amiri; Elaheh Esfandiari; Bita Geramizadeh
Journal:  Iran J Med Sci       Date:  2012-12

6.  Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study.

Authors:  Thomas Payne; Matilde Sassani; Ellen Buckley; Sarah Moll; Adriana Anton; Matthew Appleby; Seema Maru; Rosie Taylor; Alisdair McNeill; N Hoggard; Claudia Mazza; Iain D Wilkinson; Thomas Jenkins; Thomas Foltynie; O Bandmann
Journal:  BMJ Open       Date:  2020-08-05       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.